A Phase 2 Randomized Study Comparing Radium Ra 223 Dichloride Plus Enzalutamide With Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

Trial Profile

A Phase 2 Randomized Study Comparing Radium Ra 223 Dichloride Plus Enzalutamide With Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs Enzalutamide (Primary) ; Radium 223 chloride
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2018 Planned End Date changed from 1 Jun 2019 to 1 Nov 2019.
    • 05 Apr 2018 Status changed from recruiting to active, no longer recruiting.
    • 04 Sep 2015 Planned number of patients changed from 35 to 50 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top